Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Raffaele Piscitelli"'
Autor:
Francesca Calabrese, Alberto Regattieri, Raffaele Piscitelli, Marco Bortolini, Francesco Gabriele Galizia
Publikováno v:
Applied Sciences, Vol 12, Iss 9, p 4749 (2022)
Extracting representative feature sets from raw signals is crucial in Prognostics and Health Management (PHM) for components’ behavior understanding. The literature proposes various methods, including signal processing in the time, frequency, and t
Externí odkaz:
https://doaj.org/article/1f03ddd6acfd41aebee2b9f1f2f41054
Autor:
Rosanna Ruggiero, Federica Fraenza, Cristina Scavone, Gabriella di Mauro, Raffaele Piscitelli, Annamaria Mascolo, Carmen Ferrajolo, Concetta Rafaniello, Liberata Sportiello, Francesco Rossi, Annalisa Capuano
Publikováno v:
Frontiers in Pharmacology, Vol 11 (2020)
BackgroundThe introduction of immune checkpoint inhibitors (ICIs) in clinical practice has brought significant benefits for patients. Seven ICIs are available in Europe: nivolumab, pembrolizumab, atezolizumab, avelumab, durvalumab, cemiplimab, and ip
Externí odkaz:
https://doaj.org/article/9c79017502904dcc95473c0b9de2f076
Autor:
Michela Piezzo, Roberta D’Aniello, Ilaria Avallone, Bruno Barba, Daniela Cianniello, Stefania Cocco, Antonio D’Avino, Germira Di Gioia, Vincenzo Di Lauro, Giuseppina Fusco, Raffaele Piscitelli, Claudia von Arx, Michelino De Laurentiis, Piera Maiolino
Publikováno v:
Pharmaceutics, Vol 13, Iss 5, p 684 (2021)
Background: The introduction of trastuzumab biosimilars in clinical practice plays an important role in promoting the sustainability of healthcare systems. By contrast, the switching process can be challenging to the clinics. This survey describes th
Externí odkaz:
https://doaj.org/article/606ff46d6a98435db203621155ad3571
Autor:
Simona Cammarota, Anna Citarella, Antonella Guida, Valeria Conti, Teresa Iannaccone, Maria Elena Flacco, Francesca Bravi, Cristina Naccarato, Antonella Piscitelli, Raffaele Piscitelli, Alfredo Valente, Giulio Calella, Nicola Coppola, Giustino Parruti
Publikováno v:
PLoS ONE, Vol 14, Iss 7, p e0219396 (2019)
Background & aimsHepatitis C (HCV) is associated with several extrahepatic manifestations, and estimates of the hospitalization burden related to these comorbidities are still limited. The aim of this study is to quantify the hospitalization risk ass
Externí odkaz:
https://doaj.org/article/b7594082c36849a1bd2ce842956257c1
Autor:
Carmine D'Aniello, Maria Giuseppa Vitale, Azzurra Farnese, Lorenzo Calvetti, Maria Maddalena Laterza, Carla Cavaliere, Chiara Della Pepa, Vincenza Conteduca, Anna Crispo, Ferdinando De Vita, Francesco Grillone, Enrico Ricevuto, Michele De Tursi, Rocco De Vivo, Marilena Di Napoli, Sabrina Chiara Cecere, Gelsomina Iovane, Alfonso Amore, Raffaele Piscitelli, Giuseppe Quarto, Salvatore Pisconti, Gennaro Ciliberto, Piera Maiolino, Paolo Muto, Sisto Perdona, Massimiliano Berretta, Luca Galli, Giacomo Cartenì, Ugo De Giorgi, Sandro Pignata, GAETANO FACCHINI, Sabrina Rossetti
Publikováno v:
Frontiers in Pharmacology, Vol 7 (2016)
Axitinib is an oral angiogenesis inhibitor, currently approved for treatment of metastatic renal cell carcinoma (mRCC) after failure of prior treatment with Sunitinib or cytokine. The present study is an Italian Multi-Institutional Retrospective Anal
Externí odkaz:
https://doaj.org/article/c85d8a1442414098808758b0ebabfe41
Autor:
Sabrina Chiara Cecere, Sabrina Rossetti, Carla Cavaliere, Chiara Della Pepa, Marilena Di Napoli, Anna Crispo, Gelsomina Iovane, Raffaele Piscitelli, Domenico Sorrentino, Gennaro Ciliberto, Piera Maiolino, Paolo Muto, Sisto Perdonà, Massimiliano Berretta, Sandro Pignata, Gaetano Facchini, Carmine D'Aniello
Publikováno v:
Frontiers in Pharmacology, Vol 7 (2016)
Pazopanib is an oral angiogenesis inhibitor, currently approved for treatment of metastatic renal cell carcinoma (mRCC) and soft tissue sarcoma. The present study analyzed the outcomes of pazopanib in first-line treatment of mRCC, in a single Italian
Externí odkaz:
https://doaj.org/article/33b38a316d8b4a8882ef32d84dc12c34
Autor:
Marcello Moccia, Giuseppina Affinito, Giulia Berera, Giuseppina Marrazzo, Raffaele Piscitelli, Antonio Carotenuto, Maria Petracca, Roberta Lanzillo, Maria Triassi, Vincenzo Brescia Morra, Raffaele Palladino
Publikováno v:
Journal of neurology. 269(12)
Aims We aim to provide real-world evidence on the use of ocrelizumab for treating multiple sclerosis (MS), with specific regard to prescription pattern, adherence, persistence, healthcare resource utilization and related costs, also in relation to ot
Autor:
Roberta D’Aniello, Piera Maiolino, Vincenzo Di Lauro, Ilaria Avallone, Daniela Cianniello, Germira Di Gioia, Giuseppina Fusco, Michelino De Laurentiis, Stefania Cocco, Antonio D’Avino, Claudia von Arx, Raffaele Piscitelli, Michela Piezzo, Bruno Barba
Publikováno v:
Pharmaceutics, Vol 13, Iss 684, p 684 (2021)
Pharmaceutics
Volume 13
Issue 5
Pharmaceutics
Volume 13
Issue 5
Background: The introduction of trastuzumab biosimilars in clinical practice plays an important role in promoting the sustainability of healthcare systems. By contrast, the switching process can be challenging to the clinics. This survey describes th
Autor:
Simona, Cammarota, Valeria, Conti, Antonella, Guida, Teresa, Iannaccone, Raffaele, Piscitelli, Alfredo, Valente, Luigi, Di Gregorio, Vincenzo, Passaro, Anna, Citarella
Publikováno v:
Recenti progressi in medicina. 111(2)
Low back pain is one of the most frequent causes of consultation of the General Practitioner (GP). The purpose of the present study is to analyze the therapeutic management of low back pain, in relation to pain intensity, in the primary care setting
Autor:
Annalisa Capuano, Rosanna Ruggiero, Federica Fraenza, Carmen Ferrajolo, Gabriella di Mauro, Cristina Scavone, Liberata Sportiello, Raffaele Piscitelli, Annamaria Mascolo, Francesco Rossi, Concetta Rafaniello
Publikováno v:
Frontiers in Pharmacology
Frontiers in Pharmacology, Vol 11 (2020)
Frontiers in Pharmacology, Vol 11 (2020)
Background The introduction of immune checkpoint inhibitors (ICIs) in clinical practice has brought significant benefits for patients. Seven ICIs are available in Europe: nivolumab, pembrolizumab, atezolizumab, avelumab, durvalumab, cemiplimab, and i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7063f845cbaaf1dbed33aa0806ff6720
http://hdl.handle.net/11591/431692
http://hdl.handle.net/11591/431692